TY - JOUR
T1 - Covid-19-vaccins in het deltatijdperk
AU - Harris, Vanessa C.
AU - de Jong, Menno D.
AU - Prins, Jan M.
PY - 2021/9/21
Y1 - 2021/9/21
N2 - 1,5 years into the pandemic, SARS-CoV-2 remains a dynamic and evolving disease. Growing proportions of the population have been vaccinated, but what degree of protection does vaccination actually offer, particularly in the face of an evolving virus and the emergence of viral variants? Here we explore the limits of vaccine protection -providing an overview of emerging data on how well vaccines protect against mild and asymptomatic disease, vaccine effectiveness against the backdrop of variants such as the Delta, and the implications for SARS-CoV-2 transmission. We assess the continued risks for our vulnerable elderly and immune-compromised patient populations, and whether emerging literature should impact our diagnostic strategies.
AB - 1,5 years into the pandemic, SARS-CoV-2 remains a dynamic and evolving disease. Growing proportions of the population have been vaccinated, but what degree of protection does vaccination actually offer, particularly in the face of an evolving virus and the emergence of viral variants? Here we explore the limits of vaccine protection -providing an overview of emerging data on how well vaccines protect against mild and asymptomatic disease, vaccine effectiveness against the backdrop of variants such as the Delta, and the implications for SARS-CoV-2 transmission. We assess the continued risks for our vulnerable elderly and immune-compromised patient populations, and whether emerging literature should impact our diagnostic strategies.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85122647598&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34854624
M3 - Article
C2 - 34854624
VL - 165
JO - Nederlands tijdschrift voor geneeskunde
JF - Nederlands tijdschrift voor geneeskunde
SN - 0028-2162
IS - 41
M1 - D6386
ER -